The regulatory agency has authorized the sale of the drugmaker's generic version of Mylan's EpiPen.
Insys Therapeutics, Cardinal Health and McKesson are just some of the public companies that could be affected by the Trump administration directive.
In the August Action Alerts PLUS members' call, Jim Cramer and Jeff Marks, Senior Portfolio Analyst of Action Alerts PLUS, discuss the portfolio's new edition of Amgen.
The healthcare space continues to be ripe for investment opportunity. Here are three stocks that won't make your portfolio sick.
The market rally will start the week on shaky footing after a tough selloff Friday amid Turkey's currency crisis. Will Tesla get sold this week?
They pulled the plus on the Rite Aid-Alberstons merger ahead of the vote -- listen to Cramer react to that now!
Innate Immunotherapeutics of Australia is the biopharmaceutical company at the center of the insider trading charges leveled against New York Rep. Chris Collins.
Rite Aid's generic drug purchasing power is likely much lower than previously forecast. What does this mean for CVS? Here are some answers.
Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.